News | Cardiovascular Ultrasound | June 13, 2016

Calculating Aortic Flow Rate Superior Test for Patient Risk Stratification

Mayo Clinic study finds echocardiography suitable test to evaluate heart function via dobutamine response

ASE 2016, Mayo Clinic study, echocardiography, aortic flow rate, patient risk stratification

June 13, 2016 — Researchers from Mayo Clinic believe they have found a better way to risk stratify some of their most fragile patients.

Patients with reduced left ventricular ejection fraction (LFLGAS) being evaluated with dobutamine, a medically induced “stressor,” to view their heart function at work need special care. Looking at a cohort of these patients, the researchers found that using echocardiography to measure their aortic flow rate was a good predictor for their risk. “Our work highlights, for the first time, the importance of calculating aortic valve flow rate to risk stratify patients undergoing dobutamine stress echo for a low-flow, low-gradient aortic stenosis. We showed that flow rate goes above and beyond contractile reserve, which is what is being used right now, to risk stratify these patients,” said Said Alsidawi, M.D.

Researchers on the study, Low-flow, Low-gradient Aortic Stenosis: Prognostic Value of Flow Rates vs. Stroke Volume During Dobutamine Echocardiography, included Alsidawi, Robert B. McCully, Christopher G. Scott, Sorin V. Pislaru, Patricia A. Pellikka, Mackram F. Eleid, Jae K. Oh, and Vuyisile T. Nkomo from the Division of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minn.

This finding could be useful for many clinicians as patients presenting with low ejection fractions (EF) could be exhibiting an early sign of heart failure. These clinicians need good diagnostic options to assess whether valve replacement surgery or other therapies are needed.

Alsidawi presented a poster based on this research during the American Society of Echocardiography 27th Annual Scientific Sessions, June 10-14 in Seattle. This research was submitted as part of the “Valvular Heart Disease” topic area.

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init